• +1-646-491-9876
    • +91-20-67278686

    Search

    Polycythemia Vera - Pipeline Review, H1 2017

    Polycythemia Vera - Pipeline Review, H1 2017

    • Report Code ID: RW0001709468
    • Category Pharmaceuticals
    • No. of Pages 68
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Polycythemia Vera - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

    Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 3 and 3 respectively.

    Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Polycythemia Vera - Overview
    Polycythemia Vera - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Polycythemia Vera - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Polycythemia Vera - Companies Involved in Therapeutics Development
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd
    Galena Biopharma Inc
    Gilead Sciences Inc
    Italfarmaco SpA
    Karus Therapeutics Ltd
    Nerviano Medical Sciences Srl
    Novartis AG
    PharmaEssentia Corp
    Polycythemia Vera - Drug Profiles
    anagrelide hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dasatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    givinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    idelalisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KA-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-009 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-012 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NMSP-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    peginterferon alfa-2a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ropeginterferon alfa-2b - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sonidegib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polycythemia Vera - Dormant Projects
    Polycythemia Vera - Discontinued Products
    Polycythemia Vera - Product Development Milestones
    Featured News & Press Releases
    Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
    Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
    Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
    May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
    May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
    Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
    Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
    Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
    Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
    Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
    Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Polycythemia Vera, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Polycythemia Vera - Pipeline by Galena Biopharma Inc, H1 2017
    Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2017
    Polycythemia Vera - Pipeline by Italfarmaco SpA, H1 2017
    Polycythemia Vera - Pipeline by Karus Therapeutics Ltd, H1 2017
    Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Polycythemia Vera - Pipeline by Novartis AG, H1 2017
    Polycythemia Vera - Pipeline by PharmaEssentia Corp, H1 2017
    Polycythemia Vera - Dormant Projects, H1 2017
    Polycythemia Vera - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Polycythemia Vera, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd
    Galena Biopharma Inc
    Gilead Sciences Inc
    Italfarmaco SpA
    Karus Therapeutics Ltd
    Nerviano Medical Sciences Srl
    Novartis AG
    PharmaEssentia Corp

    Request for Sample

    Report Url http://www.reportsweb.com//polycythemia-vera-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//polycythemia-vera-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//polycythemia-vera-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments